Drug intelligence / Profile preview

M650

Development stage: Preclinical
Lead developer: Mestag Therapeutics
Modality: Antibody-Based Therapeutics

Overview

M650 is a preclinical-stage antibody therapeutic being developed by Mestag Therapeutics for the treatment of inflammatory and autoimmune diseases. The program was identified through Mestag's proprietary research platform, which focuses on the role of fibroblasts in immune system regulation and chronic inflammation. While the specific molecular target of M650 has not been publicly disclosed as of early 2026, the asset represents a key component of the company's pipeline aimed at developing first-in-class therapies for immune-mediated conditions by modulating fibroblast-immune cell interactions.

Beyond the preview

Go deeper on M650.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M650.

Explore the full profile